Methotrexate Sodium (Trexall/Xatmep)

ChemotherapyApproved for: NSCLC, SCLC Methotrexate Sodium (Trexall/ Xatmep) Related Research News FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCClinical Research Demonstrates Positive Impact of Genomic Testing for Patients with Non-Small Cell Lung CancerA Multicenter Study on the...
|
June 1, 2021
|

Doxorubicin Hydrochloride (Totect/Zinecard)

ChemotherapyApproved for: NSCLC, SCLC Etoposide is a FDA-approved Chemotherapy for non-small cell lung cancer (NSCLC) that is metastatic or small cell lung cancer  (SCLC) that is metastatic. Related Research News BMS presents positive four-year results for Opdivo combination in...
|
June 1, 2021
|

Etoposide

ChemotherapyApproved for: SCLC Etoposide is a FDA-approved Chemotherapy for small cell lung cancer (SCLC). Related Research News FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCClinical Research Demonstrates Positive Impact of Genomic Testing for Patients with Non-Small Cell...
|
June 1, 2021
|

Gemcitabine Hydrochloride (Gemzar/Infugem)

ChemotherapyApproved for: NSCLC Gemcitabine Hydrochloride (Gemzar/ Infugem) approved Chemotherapy for Non-small cell lung cancer (NSCLC) that is locally advanced or metastatic and cannot be removed by surgery. It is used with cisplatin. Related Research News FDA Approves Repotrectinib for...
|
June 1, 2021
|

Carboplatin (Paraplatin)

ChemotherapyApproved for: NSCLC, SCLC Carboplatin + paclitaxel (carbo taxol) is given to shrink tumors and improve symptoms of lung cancer. If the disease is not metastatic (spread to areas of the body outside the lungs), carboplatin + paclitaxel may...
|
June 1, 2021
|

Docetaxel (Taxotere)

ChemotherapyApproved for: NSCLC Docetaxel (Taxotere) approved Chemotherapy for Non-small cell lung cancer (NSCLC) that is locally advanced or has metastasized. It is used: Alone in patients whose cancer has not gotten better after platinum chemotherapy With cisplatin in patients whose...
|
June 1, 2021
|

Bevacizumab (Avastin/Mvasi/Zirabev)

ChemotherapyApproved for: NSCLC Bevacizumab (Avastin/Mvasi/Zirabev) approved Chemotherapy for Nonsquamous non-small cell lung cancer (NSCLC) that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred. It is used with carboplatin and paclitaxel as first-line therapy. This...
|
June 1, 2021
|

Necitumumab (Portrazza)

ChemotherapyApproved for: NSCLC Necitumumab (Portrazza) is a FDA-approved Chemotherapy for Squamous non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment. Related Research News FDA Approves Repotrectinib for...
|
May 31, 2021
|

Lurbinectedin (Zepzelca)

ChemotherapyApproved for: SCLC Lurbinectedin was approved for Small Cell Lung Cancer (SCLC) that is metastatic. It is used in adults whose disease has gotten worse during or after treatment with platinum chemotherapy. This use is approved under FDA’s Accelerated...
|
March 19, 2021
|